GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celltrion Inc (XKRX:068270) » Definitions » Institutional Ownership

Celltrion (XKRX:068270) Institutional Ownership : 12.10% (As of Apr. 27, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Celltrion Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Celltrion's institutional ownership is 12.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Celltrion's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Celltrion's Float Percentage Of Total Shares Outstanding is 0.00%.


Celltrion Institutional Ownership Historical Data

The historical data trend for Celltrion's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celltrion Institutional Ownership Chart

Celltrion Historical Data

The historical data trend for Celltrion can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 12.43 12.60 12.74 12.79 12.91 13.17 10.44 11.94 11.99 12.10

Celltrion Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Celltrion (XKRX:068270) Business Description

Traded in Other Exchanges
N/A
Address
13-6 SongDo-Dong, Yeonsu-gu, Incheon City, KOR, 406-840
Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer, and others.

Celltrion (XKRX:068270) Headlines

No Headlines